Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS have?
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS has 556 citations in the OpenAlex counts ScholarIQ stores.
When was Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS published?
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS has 2020 year in the ScholarIQ index.
What is the open-access status of Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS?
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS has bronze oa status in the ScholarIQ index.
What is the DOI of Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS?
The DOI for Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS is on the source record.
What is the PMID of Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS?
The PMID for Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS is on the source record.
What is the OpenAlex record for Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS?
The OpenAlex for Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS is on the source record.